A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris

In the continued absence of an effective anti-HIV vaccine, approximately 2 million new HIV infections occur every year, with over 95% of these in developing countries. Calls have been made for the development of anti-HIV drugs that can be formulated for topical use to prevent HIV transmission during...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Protein Expr Purif
Autors principals: Cerini, Fabrice, Gaertner, Hubert, Madden, Knut, Tolstorukov, Ilya, Brown, Scott, Laukens, Bram, Callewaert, Nico, Harner, Jay C., Oommen, Anna M., Harms, John T., Sump, Anthony R., Sealock, Robert C., Peterson, Dustin J., Johnson, Scott K., Abramson, Stephan B., Meagher, Michael, Offord, Robin, Hartley, Oliver
Format: Artigo
Idioma:Inglês
Publicat: Academic Press 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4725576/
https://ncbi.nlm.nih.gov/pubmed/26506568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pep.2015.10.011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars